gabapentin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
gabapentin: clinical details
Prescribing considerations
- Confirm a licensed indication, agree treatment goals and periodically review benefit and continued need.
- Assess renal function and clinically important deterioration.
- Assess respiratory disease, frailty, neurological disease and concurrent CNS depressants, particularly opioids.
- Discuss dependence, addiction, tolerance and withdrawal, including eventual discontinuation.
- Review previous substance or medicine misuse and monitor for signs of misuse.
- Use caution in mixed seizure disorders with absence seizures and in myasthenia gravis.
- Avoid abrupt withdrawal, particularly when treating epilepsy.
Contraindications and cautions
- Hypersensitivity to gabapentin or any excipient in the selected product.
Monitoring
- Clinical response, adverse effects and ongoing need
- Renal function where impairment is present or likely to change
- Sedation, falls and respiratory depression in higher-risk patients
- Mood, suicidal thoughts and behavioural change
- Severe skin or systemic hypersensitivity reactions
- Dependence, misuse and withdrawal symptoms
- Infant feeding, alertness and weight gain during breastfeeding when applicable
Clinical pharmacology
Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels. It is not appreciably protein-bound or metabolised, does not induce hepatic drug-metabolising enzymes, and is excreted unchanged by the kidneys. Absorption is non-linear; routine plasma concentration monitoring is not generally required.
Formulation and product differences
- Products include film-coated tablets, hard capsules and oral solutions; check product-specific administration instructions and excipients.
- Selected oral solutions contain propylene glycol, parabens, sodium and potassium, which may matter in young children, pregnancy or breastfeeding, renal or hepatic disease, and controlled electrolyte diets.
- The Brown & Burk oral solution is sugar-free and has product-specific instructions for compatible NG or PEG tubes; do not extrapolate these to other liquids.
- Oral solutions require an appropriate measuring device and have product-specific storage and after-opening requirements.
- Some tablets are scored and divisible, but capsules should be swallowed whole.
gabapentin preparations and strengths
Capsule
Route: Oral
Strengths: 100 mg, 300 mg, 400 mg
Oral solution
Route: Oral
Strengths: 50 mg/mL
Tablet
gabapentin interactions
Tell the prescriber or pharmacist about prescription, non-prescription and herbal medicines, especially those causing sedation.
Opioids, including morphine
Can increase sleepiness, sedation and respiratory depression; morphine may also increase gabapentin exposure.
Other central nervous system depressants
Sedatives, sleeping medicines, some antidepressants, antipsychotics and sedating supplements may worsen dizziness, impaired alertness or breathing problems.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.